Merus Completes Acquisition of Surgestone®, Provames®, Tredemine® and Speciafoldine® Rights from Sanofi

TORONTO, March 7, 2016 /CNW/ – Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] announced today that it has completed  the previously announced acquisition of rights to Surgestone®, Provames®, Tredemine®…